Drugs / pp65-shLAMP DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02465268 | Aug 2016 → Nov 2023 | astrocytoma (excluding glioblastoma), glioblastoma | University of Florida | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pp65-shLAMP DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465268 ↗ |
| Action | Activate | “a vaccine that activates your immune system” NCT02465268 ↗ |
| Modality | Vaccine | “an investigational dendritic cell vaccine” NCT02465268 ↗ |
| Route | Subcutaneous | “by giving the pp65 DC vaccine as a shot under the skin” NCT02465268 ↗ |